Logo image of CYAD.BR

CELYAD ONCOLOGY (CYAD.BR) Stock Fundamental Analysis

EBR:CYAD - Euronext Brussels - BE0974260896 - Common Stock - Currency: EUR

0.479  +0.01 (+2.79%)

Fundamental Rating

2

CYAD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. CYAD may be in some trouble as it scores bad on both profitability and health. CYAD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CYAD has reported negative net income.
CYAD had a negative operating cash flow in the past year.
CYAD had negative earnings in each of the past 5 years.
In the past 5 years CYAD always reported negative operating cash flow.
CYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFCYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -58.66%, CYAD is not doing good in the industry: 63.38% of the companies in the same industry are doing better.
The Return On Equity of CYAD (-1139.73%) is worse than 71.83% of its industry peers.
Industry RankSector Rank
ROA -58.66%
ROE -1139.73%
ROIC N/A
ROA(3y)-106.06%
ROA(5y)-75.47%
ROE(3y)-740.65%
ROE(5y)-467.64%
ROIC(3y)N/A
ROIC(5y)N/A
CYAD.BR Yearly ROA, ROE, ROICCYAD.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

With an excellent Gross Margin value of 93.55%, CYAD belongs to the best of the industry, outperforming 91.55% of the companies in the same industry.
CYAD's Gross Margin has been stable in the last couple of years.
CYAD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.32%
CYAD.BR Yearly Profit, Operating, Gross MarginsCYAD.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K -600K -800K

More info and screens

3

2. Health

2.1 Basic Checks

CYAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CYAD remains at a similar level compared to 1 year ago.
CYAD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CYAD is higher compared to a year ago.
CYAD.BR Yearly Shares OutstandingCYAD.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYAD.BR Yearly Total Debt VS Total AssetsCYAD.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

CYAD has an Altman-Z score of -1.89. This is a bad value and indicates that CYAD is not financially healthy and even has some risk of bankruptcy.
CYAD has a Altman-Z score (-1.89) which is in line with its industry peers.
A Debt/Equity ratio of 1.49 is on the high side and indicates that CYAD has dependencies on debt financing.
CYAD's Debt to Equity ratio of 1.49 is on the low side compared to the rest of the industry. CYAD is outperformed by 63.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF N/A
Altman-Z -1.89
ROIC/WACCN/A
WACC7.61%
CYAD.BR Yearly LT Debt VS Equity VS FCFCYAD.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 2.29 indicates that CYAD has no problem at all paying its short term obligations.
The Current ratio of CYAD (2.29) is comparable to the rest of the industry.
CYAD has a Quick Ratio of 2.14. This indicates that CYAD is financially healthy and has no problem in meeting its short term obligations.
CYAD has a Quick ratio of 2.14. This is comparable to the rest of the industry: CYAD outperforms 56.34% of its industry peers.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 2.14
CYAD.BR Yearly Current Assets VS Current LiabilitesCYAD.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.23% over the past year.
The Revenue has grown by 82.35% in the past year. This is a very strong growth!
CYAD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.73% yearly.
EPS 1Y (TTM)57.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.88%
Revenue 1Y (TTM)82.35%
Revenue growth 3YN/A
Revenue growth 5Y98.73%
Sales Q2Q%196.55%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYAD.BR Yearly Revenue VS EstimatesCYAD.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2023 2024 2M 4M 6M 8M
CYAD.BR Yearly EPS VS EstimatesCYAD.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYAD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYAD.BR Price Earnings VS Forward Price EarningsCYAD.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYAD.BR Per share dataCYAD.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYAD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELYAD ONCOLOGY

EBR:CYAD (5/6/2025, 7:00:00 PM)

0.479

+0.01 (+2.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-02 2025-04-02/amc
Earnings (Next)09-25 2025-09-25
Inst Owners55.35%
Inst Owner ChangeN/A
Ins Owners0.51%
Ins Owner ChangeN/A
Market Cap10.82M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 58.19
P/FCF N/A
P/OCF N/A
P/B 21.18
P/tB 102.1
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.01
BVpS0.02
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.66%
ROE -1139.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.55%
FCFM N/A
ROA(3y)-106.06%
ROA(5y)-75.47%
ROE(3y)-740.65%
ROE(5y)-467.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.32%
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.22%
Cap/Sales 63.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.29
Quick Ratio 2.14
Altman-Z -1.89
F-Score3
WACC7.61%
ROIC/WACCN/A
Cap/Depr(3y)50.8%
Cap/Depr(5y)39.13%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.88%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)82.35%
Revenue growth 3YN/A
Revenue growth 5Y98.73%
Sales Q2Q%196.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.64%
OCF growth 3YN/A
OCF growth 5YN/A